Clinical trialNCT05687110RecruitingPhase 1Interventional

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

SponsorNational Cancer Institute (NCI)Enrollment43Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has become damaged as cells grow and divide. Cancer cells that cannot repair their damaged DNA die. This medication may help shrink or stabilize cancer with a mutation in DNA repair genes.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Geoffrey I Shapiro
Dana-Farber - Harvard Cancer Center LAO
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Active, not recruiting

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Sharonlin Bhardwaj
Recruiting
Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Active, not recruiting
Uc San Diego Moores Cancer Center
La Jolla, California, United States
Shumei Kato
Recruiting
Los Angeles General Medical Center
Los Angeles, California, United States
Varsha Tulpule
Recruiting
Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Varsha Tulpule
Recruiting
Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
Active, not recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Active, not recruiting
Uc San Diego Medical Center - Hillcrest
San Diego, California, United States
Shumei Kato
Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Gini F. Fleming
Recruiting
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, United States
A P. Chen
Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Active, not recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Gerburg M. Wulf
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Geoffrey I. Shapiro
Recruiting
Nyu Langone Hospital - Long Island
Mineola, New York, United States
Nancy Chan
Recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Nancy Chan
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
John L. Hays
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Debra L. Richardson
Recruiting
Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Vaia Florou
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Michael Schweizer
Recruiting
University of Washington Medical Center - Montlake
Seattle, Washington, United States
Michael Schweizer
Recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, United States
Jeremy Kratz
Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Jeremy Kratz
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Novobiocin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Jul 2023
Primary completion: 1 Jul 2028
Completion: 1 Jul 2028
Last update posted: 3 Aug 2026
Registered enrollment: 43
Registry id: NCT05687110

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.